Please try another search
For the nine months ended 30 September 2021,Trillium Therapeutics Inc revenues decreased 91% to $10K.Net loss decreased 7% to $48.6M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Lower net lossreflects Stock-based Compensation in R&D decrease of 62% to$1.9M (expense). Basic Earnings per Share excludingExtraordinary Items increased from -$0.67 to -$0.47.
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Revenue | 0 | 0.01 | 0 | 0.03 |
Gross Profit | ||||
Operating Income | -19.45 | -18.67 | -11.31 | -8.04 |
Net Income | -19.32 | -18.4 | -10.86 | -7.32 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Total Assets | 265.36 | 273.68 | 288.29 | 300.82 |
Total Liabilities | 22.2 | 14.12 | 15.3 | 21.98 |
Total Equity | 243.16 | 259.57 | 272.99 | 278.85 |
Period Ending: | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -42.55 | -28.56 | -17.08 | -22.73 |
Cash From Investing Activities | -114.35 | -51.62 | 15.76 | -35.48 |
Cash From Financing Activities | 2.64 | 2.53 | 1.63 | 290.91 |
Net Change in Cash | -154.37 | -77.76 | 0.3 | 233.02 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review